Hvidovre Hospital

Moberg Pharma Ab

Other

Ove Andersen

Jesper Eugen-Olsen

Torben Mogensen

Stine Mogensen

Charlotte Treldal

Steen B Haugaard

Birgitte Rønde Hansen

Sylvia Pulis Sundby

Janne Petersen

Sylvia Pulis

The present invention relates to compositions comprising a lipophilic local anaesthetic, preferably bupivacaine or a pharmaceutically active salt thereof, which are formulated for local administration to the mouth or throat of a subject. The compositions are useful in the treatment or alleviation of pain, burning or xerostomia of the oral cavity, pharynx, oral mucosa and pharyngeal mucosa or for use in providing local anesthesia of the oral cavity, pharynx, oral mucosa and pharyngeal mucosa. In particular in the treatment of pain, burning or xerostomia, which is caused by a disease such as oral mucositis, Burning Mouth Syndrome, Sjogren's syndrome, xerostomia, periodontitis, toothache, tonsillectomy, throat infection or mononucleosis, canker sores and aphthous stomatitis.

Pharmaceutical compositions comprising a local anaesthetic such as bupivacaine for local administration to the mouth or throat

The invention concerns a marker for low-grade inflammation and metabolic syndrome (MS) and MS-related diseases and/or low-grade inflammation-related diseases such as cardiovascular disease, ischemic heart disease and type 2 diabetes. More particularly it concerns the measurement of the concentration of soluble urokinase plasminogen activator receptor (suPAR) in human biological fluids (sputum, cystic fluid, ascites, serum, plasma, urine) as a tool of diagnosing and/or prognosticating low-grade inflammation and metabolic syndrome and the risk of development of the related diseases such as cancer, cardiovascular disease, ischemic heart disease and type 2 diabetes.

Methods of selecting and treating subjects with low-grade inflammation and metabolic disorders

The invention concerns a marker for low-grade inflammation and metabolic syndrome (MS) and MS-related diseases and/or low-grade inflammation-related diseases such as cardiovasculardisease, ischemic heart disease and type 2 diabetes. More particularly it concerns the measurement of the concentration of soluble urokinase plasminogen activator receptor (suPAR) in human biological fluids (sputum, cystic fluid, ascites, serum, plasma, urine) as a tool of diagnosing and/or prognosticating low-grade inflammation and metabolic syndrome and the risk of development of the related diseases such as cancer, cardiovascular disease, ischemic heart disease and type 2 diabetes.

Method for predicting cancer and other diseases

The present invention concerns a breakable multi-specimen storage vessel. The vessel comprises a tubular container comprising a lower end and an upper end. At least said upper end has an open end opening. The length of said container is continuously formed and provided with break portions at predetermined positions alongside thereof. Said container is adapted to be broken into a plurality of specimens. Further, an external surface of said container may be provided with a screw thread. Said screw thread is provided extending longitudinally along substantially the entire length of said tubular container and said internal surface is substantially smooth. The invention further relates to a break tool for breaking off specimens from a multi-specimen storage vessel such as a storage vessel according to the invention.

Storage vessel and a break tool for dividing such vessel

Growing community of inventors

Hellerup, Denmark

Ove Andersen